Lucid Diagnostics (NASDAQ:LUCD) Rating Increased to Hold at Wall Street Zen

Lucid Diagnostics (NASDAQ:LUCD) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

LUCD has been the subject of several other research reports. Ascendiant Capital Markets raised their price objective on shares of Lucid Diagnostics from $8.00 to $8.25 and gave the company a “buy” rating in a research note on Wednesday, December 10th. Needham & Company LLC restated a “buy” rating and set a $3.00 target price on shares of Lucid Diagnostics in a research report on Thursday. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Lucid Diagnostics in a research report on Monday, December 29th. Four analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Lucid Diagnostics currently has a consensus rating of “Moderate Buy” and an average price target of $3.94.

Lucid Diagnostics Stock Performance

NASDAQ:LUCD opened at $1.12 on Friday. The stock has a fifty day moving average price of $1.30 and a two-hundred day moving average price of $1.18. The stock has a market capitalization of $154.20 million, a price-to-earnings ratio of -1.17 and a beta of 1.18. Lucid Diagnostics has a 1 year low of $0.95 and a 1 year high of $1.80.

Lucid Diagnostics (NASDAQ:LUCD) last issued its earnings results on Thursday, March 26th. The company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.07) by ($0.03). The business had revenue of $1.50 million for the quarter, compared to the consensus estimate of $1.39 million. On average, analysts predict that Lucid Diagnostics will post -0.84 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the company. Quadrature Capital Ltd acquired a new position in shares of Lucid Diagnostics during the 2nd quarter worth $29,000. Centiva Capital LP acquired a new stake in Lucid Diagnostics in the 3rd quarter valued at about $25,000. Sprott Inc. purchased a new position in Lucid Diagnostics during the 3rd quarter valued at about $25,000. Cubist Systematic Strategies LLC purchased a new position in Lucid Diagnostics during the 1st quarter valued at about $39,000. Finally, SG Americas Securities LLC acquired a new position in Lucid Diagnostics during the third quarter worth about $26,000. Hedge funds and other institutional investors own 74.01% of the company’s stock.

Lucid Diagnostics News Roundup

Here are the key news stories impacting Lucid Diagnostics this week:

• Positive Sentiment: Won expanded access with the U.S. Department of Veterans Affairs and is pushing for Medicare/commercial payer wins, which could materially enlarge addressable market and reimbursement prospects. Lucid Diagnostics signals expanded VA market access and 29% sequential test volume
• Positive Sentiment: Strong test-volume growth: management reported ~29% sequential growth in EsoGuard tests processed (3,664 tests in Q4), indicating improving commercial traction. Q4 2025 Earnings Call Highlights
• Positive Sentiment: Revenue slightly beat consensus ($1.50M reported vs. $1.39M expected), showing top-line improvement versus prior-year quarter. Zacks: Reports Q4 Loss, Beats Revenue Estimates
• Positive Sentiment: Company highlighted strengthened clinical evidence with positive real‑world data (largest reported experience for esophageal precancer detection), which can support adoption and payer discussions. PR Newswire: Business Update & Financial Results
• Positive Sentiment: Analyst backing: Needham reaffirmed a “buy” rating with a $3.00 price target, representing sizable upside from current levels if execution continues. Benzinga: Needham Reaffirms Buy
• Neutral Sentiment: Company hosted a Q4 business update and provided slides/webcast; multiple earnings-call transcripts and slides are available for investors evaluating management commentary and forward guidance. Quarterly Press Release / Slide Deck
• Negative Sentiment: Earnings miss on profitability: Lucid reported a Q4 EPS of -$0.10 vs. consensus -$0.07, a larger-than-expected loss that likely drove near-term selling pressure despite revenue strength. InsiderMonkey: Q4 2025 Earnings Call Transcript

About Lucid Diagnostics

Lucid Diagnostics is a molecular diagnostics company focused on improving early detection of oral and oropharyngeal cancers. The company’s flagship offering, the LucidDx Oral Cytology Brush Test, combines a minimally invasive brush biopsy tool with proprietary laboratory analysis to identify cellular abnormalities indicative of malignancy. Samples collected in dental and medical offices are sent to Lucid’s CLIA-certified and CAP-accredited laboratory, where advanced imaging and cytopathology workflows generate diagnostic reports for clinicians and patients.

Since commencing commercial operations, Lucid Diagnostics has worked to integrate its testing platform into dental practices, oral surgery clinics and ENT specialists across the United States.